Robert J Straka

Dr. Robert J Straka

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2011 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
MWMary Wojczynski
Mary Wojczynski
SGStephen P Glasser
Stephen P Glasser
AOAlbert Oberman
Albert Oberman
EKEdmond K Kabagambe
Edmond K Kabagambe
PHPaul N Hopkins
Paul N Hopkins
DADonna K Arnett
Donna K Arnett
Background: Postprandial lipemia (PPL) is likely a risk factor for cardiovascular disease but these changes have not been well described and characterized in a large cohort. We assessed acute changes in the size and concentration of total and subclasses of LDL, HDL, and VLDL particles in response to a high-fat meal. Participants (n = 1048) from the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN) Study who ingested a high-fat meal were included in this analysis. Lipids were measured at 0 hr (fasting), 3.5 hr, and 6 hr after a standardized fat meal. Particle size distributions were determined using nuclear magnetic resonance spectroscopy. Analyses were stratified by baseline triglycerides (normal vs. elevated) and gender. The effect of PPL on changes in lipoprotein subclasses was assessed using repeated measures ANOVA. Results: Postprandially, LDL-C, HDL-C, VLDL-C, and triglycerides increased regardless of baseline triglyceride status, with the largest increases in VLDL-C and TG; however, those with elevated triglycerides demonstrated larger magnitude of response. Total LDL particle number decreased over the 6-hour time interval, mostly from a decrease in the number of small LDL particles. Similarly, total VLDL particle number decreased due to reductions in medium and small VLDL particles. Large VLDL particles and chylomicrons demonstrated the largest increase in concentration. HDL particles demonstrated minimal overall changes in total particle number. Conclusions: We have characterized the changes in LDL and VLDL particle number, and their subclass patterns following a high-fat meal.

1 May 2017 in American Journal of Therapeutics
Verified
Journal Article
Open access
RSRobert J Straka
Robert J Straka
DKDenis J. Keohane
Denis J. Keohane
LLLarry Z. Liu
Larry Z. Liu
Switching branded to generic medications has become a common cost-containment measure. Although this is an important objective for health care systems worldwide, the impact of this practice on patient outcomes needs to be carefully considered. We reviewed the literature summarizing the potential clinical and economic consequences of switching from branded to generic medications on patient outcomes. A literature search of peer-reviewed articles published 2003–2013 using key words of “generic switching” or “substitution” was conducted using PubMed, OvidSP, and ScienceDirect. Of 30 articles identified and reviewed, most were related to the diseases of the central nervous system, especially epilepsy. Based on our review, potential impacts of switching fell into 3 broad categories: patient attitudes and adherence, clinical and safety outcomes, and cost and resource utilization. Although in many cases generics may represent an appropriate alternative to branded products, this may not always be the case. Specifically, several studies suggested that switching may negatively impact medication adherence, whereas other studies found that generic switching was associated with poorer clinical outcomes and more adverse events. In some instances, switching accomplished cost savings but did so at increased total cost of care because of increased physician visits or hospitalizations. Although in many cases generics may represent an appropriate alternative, mandatory generic switching may lead to unintended consequences, especially in certain therapeutic areas. Although further study is warranted, based on our review, it may be medically justifiable for physicians and patients to retain the right to request the branded product in certain cases.

29 June 2011 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
JTJ Trottier
J Trottier
PCP Caron
P Caron
RSRobert J Straka
Robert J Straka
OBOlivier Barbier
Olivier Barbier
Fenofibrate belongs to the group of hypolipidemic fibrates that act as activators of the peroxisome proliferator–activated receptor‐α (PPARα), which is a regulator of bile acid synthesis, metabolism,...

27 July 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
LGLi Gong
Li Gong
SLSeung‐Been Lee
Seung‐Been Lee
JWJonathan B. Wagner
Jonathan B. Wagner
XZXujia Zhou
Xujia Zhou
AGAndrea Gaedigk
Andrea Gaedigk

1 January 2009 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
RSRobert J Straka
Robert J Straka
LLLarry Z Liu
Larry Z Liu
PGPrafulla S Girase
Prafulla S Girase
ADAllyson DeLorenzo
Allyson DeLorenzo
RCRichard H Chapman
Richard H Chapman
Patients with type 2 diabetes are at increased risk of cardiovascular events, and there is an associated economic burden attached to this risk. We conducted a retrospective claims database analysis to evaluate incremental cardiovascular costs in diabetic versus non-diabetic patients hospitalized for a cardiovascular event.

1 July 2001 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
RSRobert J Straka
Robert J Straka
RTReza Taheri
Reza Taheri
SCSusan L. Cooper
Susan L. Cooper
ATAgnes W. H. Tan
Agnes W. H. Tan
JSJames C. Smith
James C. Smith